Efficacy, safety, and patient-reported outcomes of scalp micropigmentation in scarring alopecia

Objectives: Scalp micropigmentation (SMP) is a minimally invasive cosmetic procedure that creates the illusion of increased hair density through the implantation of pigment in the scalp. While it is widely used in androgenetic alopecia and post-traumatic scarring, its application in primary scarring alopecia – characterized by irreversible follicular destruction and dermal fibrosis – has not been well studied. This study aimed to evaluate the efficacy, safety, and patient-reported outcomes of SMP in individuals with stable scarring alopecia and to assess diagnosis-specific outcomes in terms of esthetic improvement and tolerability. Material and Methods: Conducted between August 2023 and February 2025, this prospective interventional study included 18 patients with stable scarring alopecia aged 18–60 years and lesion sizes ≥2 cm × 2 cm. Inclusion required disease inactivity for at least 6 months and a willingness to follow up. Exclusion criteria included active inflammation, infection, keloidal tendency, pregnancy, and immunocompromised states. All procedures were performed under ring block anesthesia. Pigment implantation was performed using a single-needle and 3RL cartridge system, targeting the upper dermis with a pointillism technique. Follow-up evaluations were conducted at 1 week, 2 weeks, 1 month, 3 months, and 6 months. Safety outcomes, including pain, edema, ecchymosis, allergic reactions, secondary infections, scarring, and pigment changes, were documented and photographed. Patient-reported satisfaction outcomes were measured through a 100 mm Visual Analog Scale (VAS) at baseline and 6 months. Statistical analysis used Wilcoxon signed-rank tests for VAS comparisons, with P < 0.05 considered statistically significant. Results: Pigment fading was observed in all patients by one month and continued to progress. Pigment diffusion occurred in 55.6% of patients by 6 months. Color changes were observed in 72.2% of cases, and touch-ups were required in all instances. Side effects were transient and included edema (66.7%), ecchymosis (33.3%), crusting (55.6%), and pain (33.3%). At 6 months, 50% of participants demonstrated a favorable esthetic response, with the highest satisfaction in frontal fibrosing alopecia (FFA) (100%) and traction alopecia (80%). The lowest response was observed in morphea and lichen planopilaris, where 80% and 66.6% of patients failed to retain at least 50% of the pigment at the end of 6 months, suggesting that SMP might not be effective in such cases as a standalone approach. VAS scores improved significantly from a baseline mean of 35.28 to 25.5 at 6 months ( P ≈ 0.002). No allergic reactions or infections were noted. Conclusion: SMP offers a safe and effective esthetic enhancement in scarring alopecia, with outcomes influenced by the degree of dermal fibrosis and disease subtype. Conditions with mild atrophy, such as FFA and traction alopecia, respond better than dense fibrotic conditions, such as morphea. SMP significantly improved patient satisfaction and visual scalp appearance, highlighting its potential as a valuable adjunct in managing the cosmetic and psychosocial burden of scarring alopecia. Further studies with larger cohorts and advanced pigment technologies are recommended to optimize outcomes in fibrotic scalp conditions.